BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
35.81
+1.45 (4.22%)
At close: Sep 30, 2026

SHA:688166 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
1,342961.06765.35998.051,180336.84
Trading Asset Securities
---50.6250.120.76
Cash & Short-Term Investments
1,342961.06765.351,0491,230337.6
Cash Growth
81.44%25.57%-27.02%-14.78%264.48%-35.02%
Accounts Receivable
403.85330.02339.5308.88307.47373.85
Other Receivables
2.619.136.6619.9118.783.75
Receivables
406.46339.14346.17328.79326.25377.59
Inventory
333.08364.25364.61344.63280.35200.06
Prepaid Expenses
---3.655.834.48
Other Current Assets
120.34124.04164.1411495.3973.27
Total Current Assets
2,2021,7891,6401,8401,938993.01
Property, Plant & Equipment
2,7902,7522,7052,4892,0761,378
Long-Term Investments
783.03671.08437.06425.86399.33348.28
Goodwill
--3.127.57.57.5
Other Intangible Assets
77.5979.5389.4893.6681.6480.84
Long-Term Accounts Receivable
4.14.12.1---
Long-Term Deferred Tax Assets
117.7594.6862.242.2823.9419.86
Long-Term Deferred Charges
414.82339.1957.4930.1826.8725.83
Other Long-Term Assets
115.9295.42156.03104.09107.73115.86
Total Assets
6,5055,8255,1535,0324,6612,970

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
125.86185.89266228.18252.19211.89
Accrued Expenses
40.3882.9772.0172.3169.0461.72
Short-Term Debt
75.04110.11115.26156.87124.38257.05
Current Portion of Long-Term Debt
602.34775.1516.96397.93313.8716.58
Current Portion of Leases
18.418.8313.6916.11.349.87
Current Income Taxes Payable
4.2710.6116.6814.0414.973.69
Current Unearned Revenue
33.0525.5628.022429.4920.33
Other Current Liabilities
78.8981.2323.7612.816.261.93
Total Current Liabilities
978.261,2801,052922.25811.52583.07
Long-Term Debt
1,8811,4901,5801,6151,576618.69
Long-Term Leases
22.1610.2110.2121.016.010.22
Long-Term Unearned Revenue
162.96167.5884.7126.252626
Other Long-Term Liabilities
30.330.3-29.82--
Total Liabilities
3,0752,9792,7272,6142,4201,228

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
435.79423.1422.47422.47422.47410
Additional Paid-In Capital
1,6011,076982.361,0571,008738.94
Retained Earnings
1,1561,0661,046897.66743.35555.05
Treasury Stock
-20.05-20.05-10.01---
Comprehensive Income & Other
-119.9-24.21-57.82-8.6417.77-25.8
Total Common Equity
3,0522,5212,3832,3692,1921,678
Minority Interest
378.04325.0142.7348.9750.0463.45
Shareholders' Equity
3,4302,8462,4262,4182,2421,742
Total Liabilities & Equity
6,5055,8255,1535,0324,6612,970

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,5992,3952,2362,2072,022902.42
Net Cash (Debt)
-1,257-1,433-1,470-1,158-791.15-564.82
Net Cash Growth
------
Net Cash Per Share
-3.03-3.42-3.50-2.75-1.91-1.39
Filing Date Shares Outstanding
435.23422.54422.11422.1422.47410
Total Common Shares Outstanding
435.23422.54422.11422.47422.47410
Working Capital
1,224508.2587.89917.491,127409.94
Book Value Per Share
7.015.975.655.615.194.09
Tangible Book Value
2,9752,4422,2912,2672,1031,590
Tangible Book Value Per Share
6.835.785.435.374.983.88
Buildings
745.52745.28728.65261.26273.4104.72
Machinery
1,3471,2711,122704.8318.41287.37
Construction In Progress
1,2031,1871,1671,7361,6661,131